Spegra Tablet
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Spegra Tablet is a fixed-dose combination of dolutegravir (an integrase strand transfer inhibitor) with emtricitabine and tenofovir alafenamide (nucleos(t)ide reverse transcriptase inhibitors). Its labelling describes it as a complete regimen for the treatment of HIV infection, taken once daily at the same time each day with or without food. It is described as controlling the infection rather than curing or preventing HIV or AIDS.
Product Information
The following description reflects information associated with dolutegravir, emtricitabine, and tenofovir alafenamide and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described as a complete once-daily regimen for the treatment of HIV infection
- Described as controlling the infection by helping the immune system work more efficiently
- Described as neither a cure for nor a means of preventing HIV or AIDS
Described Dosage & Administration
- Swallowed with water, once daily, at about the same time each day, with or without food
- Tablets should not be chewed, broken, or crushed
- The prescriber’s instructions on dose and interval should be followed, and doses should not be missed
- The full course should be completed to support recovery
Described Side Effects
Commonly described side effects include:
- Difficulty sleeping (insomnia)
- Headache
- Nausea
- Tiredness (fatigue)
- Diarrhoea
These are described as entirely temporary in most cases. Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- The medicine is described as causing dizziness, so driving should be avoided
- The doctor should be consulted if the patient is pregnant or breastfeeding
- The healthcare team’s monitoring and tests should be cooperated with during treatment
- Any persistent or severe side effect should be reviewed by a clinician
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it combines dolutegravir, emtricitabine, and tenofovir alafenamide as a complete once-daily regimen for the treatment of HIV infection. It is described as neither a cure nor a means of preventing HIV or AIDS. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling describes it as swallowed with water once daily at about the same time each day, with or without food, and not chewed, broken, or crushed. Doses should not be missed and the full course should be completed.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.